创新药械发展再获政策支持！科创100ETF华夏（588800）早盘冲高震荡

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index has seen a strong increase of 1.12% as of July 31, with significant gains in constituent stocks such as Dongxin Co., Ltd. rising by 19.99%, Shengyi Technology increasing by 12.27%, and Yuanjie Technology up by 12.18% [1] - The Huaxia Sci-Tech 100 ETF (588800) has also risen by 1.22%, with a latest price of 1.08 yuan, and has accumulated a 3.5% increase over the past week [1] - The trading volume for the Huaxia Sci-Tech 100 ETF was 48.08 million yuan, with a turnover rate of 1.64%, indicating strong liquidity and a significant growth in scale of 46.29 million yuan over the past week [1] Group 2 - The National Healthcare Security Administration held a seminar to support the high-quality development of innovative drugs and medical devices, emphasizing the significant policy, research, manufacturing, and market advantages of China's innovative drug and device industry [2] - Participants at the seminar expressed confidence in the future development of China's innovative drug and device industry, supported by the government's measures to enhance this sector [2] - Citic Securities predicts a high certainty of performance and valuation recovery in the healthcare industry by the second half of 2025, driven by favorable external conditions and domestic policy support for innovative drugs [3] - The Huaxia Sci-Tech 100 ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index, focusing on medium-sized, liquid securities with high growth potential, marking it as the first and only small-cap style index in the Sci-Tech Board [3]